SCHEMBL21990701

SCHEMBL21990701

COC(=O)c1nc(N(C)C(C)C)cc2c1CNC2=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.34
PIK3CB P42338 5/20 0.34
PIK3CG P48736 5/20 0.34
PIK3CA P42336 4/20 0.34
NPSR1 Q6W5P4 1/20 0.32
KDR P35968 3/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PARP1 P09874 1/20 0.30
PLK4 O00444 1/20 0.30
CHEK1 O14757 1/20 0.30
DAPK3 O43293 1/20 0.30
ROCK2 O75116 1/20 0.30
PRKD3 O94806 1/20 0.30
MAP4K4 O95819 1/20 0.30
CHEK2 O96017 1/20 0.30
PRKCG P05129 1/20 0.30
INSR P06213 1/20 0.30
LCK P06239 1/20 0.30
LYN P07948 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30227741 1.00 PIK3CD (0.34) PIK3CDPIK3CBPIK3CGPIK3CANPSR1
SCHEMBL23988247 0.89 CYP17A1 (0.31) PIK3CDPIK3CBPIK3CGPIK3CAPIM1
SCHEMBL30227824 0.89 CYP17A1 (0.31) PIK3CDPIK3CBPIK3CGPIK3CAPIM1
SCHEMBL21990542 0.88 NPSR1 (0.35) PIK3CDPIK3CBPIK3CGPIK3CANPSR1
SCHEMBL23988004 0.83 MAP4K1 (0.31) CYP17A1CYP3A4
SCHEMBL25099629 0.82 PIK3CD (0.32) PIK3CDPIK3CBPIK3CGPIK3CANPSR1
SCHEMBL25100219 0.81 JAK3 (0.35) PIK3CDPIK3CBPIK3CGPIK3CAALDH1A1
SCHEMBL21990455 0.79 MAP4K1 (0.36) PIK3CDPIK3CBPIK3CGPIK3CAPLK4
SCHEMBL30227903 0.79 MAP4K1 (0.36) PIK3CDPIK3CBPIK3CGPIK3CAPLK4
SCHEMBL21964197 0.79 MAP4K1 (0.35) PIK3CDPIK3CBPIK3CGPIK3CAPRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2024-06-20 US disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2022-12-22 US disclosed
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2022-12-22 US disclosed
WO-2021220185-A1 AZALACTAM COMPOUNDS AS HPK1 INHIBITORS PFIZER INC. (US) 2021-11-04 WO disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
WO-2020100027-A1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 PIK3CD 818/4885PIK3CB 698/4885PIK3CG 1165/4885
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 PIK3CD 892/4885PIK3CB 1067/4885PIK3CG 1355/4885
US-11142525-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 PIK3CD 892/4885PIK3CB 1067/4885PIK3CG 1355/4885
US-11684616-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 PIK3CD 818/4885PIK3CB 698/4885PIK3CG 1165/4885
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 PIK3CD 818/4885PIK3CB 698/4885PIK3CG 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.